

CORRECTED VERSION

(19) World Intellectual Property
Organization
International Bureau



WIPO | PCT



(10) International Publication Number
WO 2012/156532 A8

(43) International Publication Date
22 November 2012 (22.11.2012)

- (51) **International Patent Classification:**
C07K 16/32 (2006.01) *A61P 35/00* (2006.01)
A61K 39/395 (2006.01)
- (21) **International Application Number:**
PCT/EP2012/059402
- (22) **International Filing Date:**
21 May 2012 (21.05.2012)
- (25) **Filing Language:** English
- (26) **Publication Language:** English
- (30) **Priority Data:**
- | | | |
|------------|---------------------------|----|
| 11305607.1 | 19 May 2011 (19.05.2011) | EP |
| 61/499,948 | 22 June 2011 (22.06.2011) | US |
| 61/502,932 | 30 June 2011 (30.06.2011) | US |
- (71) **Applicants** (*for all designated States except US*): **INSERM (Institut National de la Santé et de la Recherche Médicale)** [FR/FR]; 101 rue de Tolbiac, F-75013 Paris (FR). **CENTRE VAL D'AURELLE - PAUL LAMARQUE** [FR/FR]; Centre Regional De Lutte Contre Le Cancer, 208, Rue Des Apothicaires - Parc Euromedecine, F-34298 Montpellier Cedex 5 (FR). **UNIVERSITE DE MONTPELLIER 1** [FR/FR]; 5 Boulevard Henri Iv Cs 19044, F-34967 Montpellier Cedex 2 (FR).
- (72) **Inventors; and**
- (75) **Inventors/Applicants** (*for US only*): **CHARDES, Thierry** [FR/FR]; Institut De Recherche En Cancerologie De Montpellier, Inserm U896 Université De Montpellier 1/, Crlc Val D'aurelle, 208 Rue Des Apothicaires, F-34298 Montpellier Cedex 5 (FR). **PELEGRIN, André** [FR/FR]; Institut De Recherche En Cancerologie De Montpellier, Inserm / Université De Montpellier 1/, Crlc Val D'aurelle, 208 Rue Des Apothicaires, F-34298 Montpellier Cedex 5 (FR). **LARBOURET, Christel** [FR/FR]; Institut De Recherche En Cancerologie De Montpellier, Inserm U896 / Université De Montpellier 1/, Crlc Val D'aurelle, 208 Rue Des Apothicaires, F-34298 Montpellier Cedex 5 (FR). **GABORIT, Nadege** [FR/IL]; Department Of Biological Regulation, The Weizmann Institute Of Science, 76100 Rehovot (IL). **LAZREK, Yassamine** [FR/FR]; Institut De Recher-

che En Cancerologie De Montpellier, Inserm U896 / Université De Montpellier 1/, Crlc Val D'aurelle, 208 Rue Des Apothicaires, F-34298 Montpellier Cedex 5 (FR).

- (74) **Agent:** **HIRSCH, Denise**; Inserm Transfert, 7 rue Watt, F-75013 Paris (FR).
- (81) **Designated States** (*unless otherwise indicated, for every kind of national protection available*): AE, AG, AL, AM, AO, AT, AU, AZ, BA, BB, BG, BH, BR, BW, BY, BZ, CA, CH, CL, CN, CO, CR, CU, CZ, DE, DK, DM, DO, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, HN, HR, HU, ID, IL, IN, IS, JP, KE, KG, KM, KN, KP, KR, KZ, LA, LC, LK, LR, LS, LT, LU, LY, MA, MD, ME, MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, OM, PE, PG, PH, PL, PT, QA, RO, RS, RU, RW, SC, SD, SE, SG, SK, SL, SM, ST, SV, SY, TH, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, ZA, ZM, ZW.
- (84) **Designated States** (*unless otherwise indicated, for every kind of regional protection available*): ARIPO (BW, GH, GM, KE, LR, LS, MW, MZ, NA, RW, SD, SL, SZ, TZ, UG, ZM, ZW), Eurasian (AM, AZ, BY, KG, KZ, RU, TJ, TM), European (AL, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LT, LU, LV, MC, MK, MT, NL, NO, PL, PT, RO, RS, SE, SI, SK, SM, TR), OAPI (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG).

Published:

- with international search report (Art. 21(3))
- with (an) indication(s) in relation to deposited biological material furnished under Rule 13bis separately from the description (Rules 13bis.4(d)(i) and 48.2(a)(viii))
- with sequence listing part of description (Rule 5.2(a))

(48) Date of publication of this corrected version:

17 July 2014

(15) Information about Correction:

see Notice of 17 July 2014

(54) **Title:** ANTI-HUMAN-HER3 ANTIBODIES AND USES THEREOF

(57) **Abstract:** The present invention provides for isolated anti-human-HER3 antibodies or fragments thereof. More particularly the present invention provides an isolated monoclonal antibody that specifically binds to the extracellular domain of HER-3 and competes for binding to the extracellular domain of human HER-3 with the antibody produced obtainable from hybridoma deposited as CNCM-I-4486. The antibodies described in the present invention are useful for the treatment of cancer.



WO 2012/156532 A8